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Deep-sequencing of a primary tumor and metastasis
from a single patient, and functional validation in culture,
reveals that TGFBR2 and FGFR2 act as drivers of gastric
cancer.quent sequencing of a primary tumor from this patientIntroduction
When talking about cancer genome studies, big does not
necessarily mean beautiful, and, as illustrated by Nadauld
and colleagues [1] in this edition of Genome Biology, the
careful analysis of just one gastric cancer patient can pro-
vide profound insights into the drivers of tumorigenesis.
Recent estimates of the worldwide gastric cancer burden
show that it is the fifth most commonly diagnosed cancer,
and the third-leading cause of cancer death [2]. Current
treatment options for early disease include surgical resec-
tion together with neoadjuvant or adjuvant chemotherapy,
but five-year survival is only <60% [3]. Patients with ad-
vanced disease are treated with chemotherapy or che-
moradiotherapy and show a median survival of around
12 months, whereas patients with a high level of expres-
sion of HER2 (also known as ERBB2, encoding receptor
tyrosine-protein kinase erbB-2) receive adjuvant trastu-
zumab (monoclonal antibody against HER2) and can be
expected to have a median survival of 16 months [3].
Overall, gastric cancer is a disease with a dismal prog-
nosis. When analyzing cancer genomes, our inclination
has always been to sequence large numbers of tumors
so as to draw the landscape of mutations. The deluge of
data that ensues makes it difficult to read the life-
history of each cancer or to appreciate the stories they
may tell.
Here, Nadauld and colleagues [1] report the identifica-
tion of candidate oncogenic drivers by undertaking exome
and whole-genome sequence analysis of tumors from a* Correspondence: da1@sanger.ac.uk
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The patient they studied presented with a diffuse gastric
cancer and a family history of the disease. Germline se-
quence analysis of CDH1 (encoding the adhesion protein
cadherin-1), a known driver, revealed an essential splice-
site mutation co-segregating within the pedigree. Subse-
and of a metastatic lesion revealed several drivers - an
amplification of the FGFR2 locus (encoding fibroblast
growth factor receptor 2) that was found exclusively in the
primary, and a deletion in the gene TGFBR2 (encoding
TGF-beta receptor type-2) found exclusively in the metas-
tasis. In this paper, it was not so much that the authors set
out to tell a story of gastric cancer - rather, the complete
story of this cancer and its evolution, and make it a good
read.The power of N = 1
In the world of clinical trials, the value of N = 1 (also
known as ‘N of 1’) studies has long been appreciated. In
this scenario, brave souls who are not yet ‘done’, or who
are unwilling to accept their fate, step forward to try
new experimental therapies. Albert Alexander, for ex-
ample, was the fourth patient to receive penicillin from
Howard Florey, and the profound anti-bacterial response
it elicited was key to its clinical development. Likewise,
dramatic responses in single patients treated with cancer
therapies such as inhibitors of the serine/threonine-protein
kinase B-raf (BRAF) and cytotoxic T-lymphocyte pro-
tein 4 (CTLA-4) have been key [4]. Yet, as cancer gen-
ome scientists, as soon as we could drown ourselves in
data, we did.
So what do the mutations identified in the tumors from
this gastric cancer patient actually tell us (Figure 1)? First,
as a germline CDH1 mutation was found, it tells us that
an early chapter in the story was loss of the wild-type al-
lele of this gene, probably coinciding with biallelic loss
of the TP53 gene (encoding cellular tumor antigen p53)
or preceding it. Thus, mutation of CDH1 and TP53 are
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Figure 1 Telling the story of a gastric cancer through sequencing and functional studies. (a) The primary gastric cancer clone carried
CDH1 and TP53 mutations. After it had metastasized to the ovary, the primary gastric cancer acquired an amplification of the FGFR2 locus (black
arrow). At this point, the primary tumor was removed by gastrectomy. Some three years later, the patient presented with abdominal masses.
Sequencing of the metastatic tumor revealed loss of TGFBR2, but no amplification of FGFR2. Loss of TGFBR2 might have occurred after the clone
had spread to the ovary (non-broken blue arrow) or alternatively might have occurred as the metastatic clone transited from the primary to the
ovary (broken blue arrow). (b) A schematic representation of the functional validation of candidate oncogenic events. A human gastric cancer cell
line harboring mutations in CDH1 and TP53, and an amplification of FGFR2, shows a significant reduction in survival in response to inhibition of
the FGF pathway. Murine gastric organoids in which Tgfbr2 is suppressed by knockdown (kd) in the context of cdh1 and Tp53 loss undergo
oncogenic transformation in vitro when grown subcutaneously (s.c.) in immunodeficient mice. The resultant tumor shows histology consistent
with diffuse gastric cancer and undergoes metastatic spread to the lungs. Abbreviations: CDH1, cadherin-1; FGF, fibroblast growth factor; FGFR,
fibroblast growth factor receptor; TGFBR2, TGF-beta receptor type-2; 3D, three-dimensional; TP53, cellular tumor antigen p53.
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FGFR2 amplification? This is most likely explained by
the early dissemination of tumor cells from the primary
lesion, which was removed by gastrectomy at presenta-
tion, to the metastatic site in the ovary, with these cells
lying dormant, only to be reanimated years later by loss
of TGFBR2. An alternative scenario could be that loss of
TGFBR2 helped a cancer cell transit from the primary
tumor to the metastatic site, where it lay in wait - either
way, distal dissemination of the tumor must have been
an early event occurring before removal of the primary.
This result challenges the dogma that metastasis occurs
late during cancer progression and suggests strategies that
kill occult cancer cells where they lie are important adju-
vants to surgery. Importantly, the early dissemination of
tumor cells poses some challenges in the clinical manage-
ment of advanced disease. First, although genomic analysis
revealed that inhibitors of FGFR2 could be used to treat
the primary lesion, they are unlikely to elicit a response in
the metastasis. As it is the metastatic abdominal mass that
represents the highest risk for the patient, treatment onthe basis of changes found in the genome of the primary
would represent wasted intervention time. This case had
just one primary and one metastasis; some cases have
dozens of metastatic lesions or synchronous primary tu-
mors, compounding the challenge of personalizing cancer
therapy. It appears that there can be no half-measures in
profiling a patient’s disease. The complexity of cancer evo-
lution does not make personalized therapy hopeless, just
challenging, and it is only through the kind of molecular
cartography described by Nadauld and colleagues [1] that
we will be able to understand this disease.
The value of N = 1 cancer-genome studies is soon to be
further tested as efforts to analyze the genomes of ‘excep-
tional responders’ - those patients whose response to ther-
apy marks them as both lucky and different - gather pace.
One particularly startling example of this approach was
the sequencing of the genome of a single small-cell lung
cancer patient, resulting in the identification of a RAD50
mutation as a factor contributing to the patient’s profound
curative response to combination chemotherapy (AZD7762 -
an inhibitor of the serine/threonine-protein kinases Chk1
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[5]. Most oncologists have stories of similar patients
who, by all reckoning, should not have survived their dis-
ease; with sequencing, we will understand why, and this
will help sculpt treatments for all patients.
The right model of cancer, not just any model
Oncogenic transformation is a complex multistep process,
and the precise number of alterations required is still an
on-going debate. Nevertheless, it is widely accepted that,
in most cancers, multiple hits contribute to the final
tumorigenic phenotype. The identification of sets of alter-
ations that cooperatively induce transformation is crucial
in order to interrogate candidate oncogenic drivers in the
appropriate genetic context. Here, Nadauld and colleagues
perform all their validation experiments in the context of
loss of CDH1 and TP53. First, by using the gastric cancer
cell-line KATOIII, which carries an amplification of
FGFR2 in addition to CDH1 and TP53 loss, they show
response to inhibitors of FGF pathway tyrosine kinases
and a therapeutic avenue that is potentially efficacious
for the primary tumor. Notably, however, inhibitors of
FGFR2 have not been formally approved for gastric can-
cer. Second, an organoid-based model, discussed below, is
used to test TGFBR2 as a tumor suppressor and to assess
its metastatic potential. Importantly, Nadauld et al. did
not choose any model - instead, they carefully selected
the right models, with functional validation of driver mu-
tations being an integral part of the story, rather than an
afterthought or footnote performed with ‘reviewer 3’ in
mind.
Organoid-based 'cancer engineering' as a
validation strategy
Next-generation sequencing studies have flooded the lit-
erature with lists of candidate cancer genes, but these are
just the ‘table of contents’ to the story of a cancer type [6].
The real story unfolds with functional studies that investi-
gate how each individual cancer is wired. In addition
to the cell-line studies described above, Nadauld and col-
leagues use a novel three-dimensional in vitro organoid
model that consists of primary epithelial and mesenchymal
gastric cells. As recently published by the same authors [7],
this model allows for in vitro 'cancer engineering' through
transfection of candidate or known oncogenic drivers into
murine primary wild-type cells from the tissue of interest.
Additionally, the presence of both epithelial and mesen-
chymal cells, and the three-dimensional nature of these
organoids, accurately reproduces the complexity of the tis-
sue of origin and its histopathology. As mentioned above,
the in vitro oncogenic transforming potential of downreg-
ulation of Tgfbr2 was tested on a background of loss of
Cdh1 and Tp53 (Cdh1-/-; Tp53-/-), with histopathological
characterization of the resulting organoids revealing a keyrole for Tgfbr2 downregulation in a diffuse gastric cancer
phenotype. Interestingly, disaggregated Cdh1-/-; Tp53-/-
organoids expressing small hairpin RNA (shRNA) target-
ing Tgfbr2, when injected subcutaneously into immunode-
ficient mice, showed increased tumor growth compared
with Cdh1-/-; Tp53-/- control cells.Furthermore, the distal
spread of cells from the injection site into the lungs of
the mice was observed, thus confirming the metastatic
potential of the Cdh1-/-; Tp53-/-; Tgfbr2 knockdown cells
(Figure 1).
The route ahead via N = 1
At heart, many of us are reductionists seeking to under-
stand simple questions through the lens of genome se-
quencing. Just as the N = 1 clinical trial has profoundly
informed us of new paths to therapy, the N = 1 cancer
genome will increasingly be used to identify the key mo-
lecular factors that drive cancer evolution and mediate
response to therapy. Recent studies, for example, have
used N = 1 approaches to define new driver mutations
and mutational signatures in melanoma and to hunt down
the clone of origin for a lethal prostate cancer [8-10].
Nadauld and colleagues further illustrate the power of
an N = 1 analysis - the advantage of combining these en-
deavors with functional studies and the value of every
cancer patient’s story.
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